IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Guy L. REED

Appl. No. To be assigned

(Divisional of U.S. Appl. No. 08/934,000,

filed: September 19, 1997)

Filed: October 3, 2001

For: Composition and Method for Enhancing Fibrinolysis Art Unit: To be assigned

Examiner: To be assigned

Confirmation No.: To be assigned

Atty. Docket:0609.4320003/JAG/AJK/TAC

Preliminary Amendment and Submission of Sequence Listing

Commissioner for Patents Washington, D.C. 20231

Sir:

In advance of prosecution, please amend the application as follows:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37

C.F.R. § 1.111 and MPEP 714; and

(C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

Please substitute the pending paragraph beginning on page 1, line 9, with the following paragraph:

This application is a divisional of U.S. Appl. No. 08/934,000, filed September 19, 1997, which disclosure is hereby incorporated by reference; said U.S. Appl. No. 08/934,000 claims priority benefit to U.S. Provisional Appl. No. 60/026,356, filed September 20, 1996, which disclosure is hereby incorporated by reference.

Please substitute the pending paragraph beginning on page 18, line 19, with the following paragraph:

DNA clones containing nucleotide sequences encoding the following antibody chains were deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20862 on September 19, 1997: light chain of 77A3 (77A3 LC), ATCC Accession No. 209290; light chain of 49C9 (49C9 LC), ATCC Accession No. 209291; light chain of 70B11 (70B11 LC), ATCC Accession No. 209292; heavy chain of 77A3 (77A3 HC), ATCC Accession No. 209287; heavy chain of 49C9 (49C9 HC), ATCC

Acession No. 209289; and heavy chain of 70B11 (70B11 HC), ATCC Accession No. 209288

Please substitute the pending paragraph beginning at page 18, line 27, with the following paragraph:

The nucleic acid molecules of the present invention include: nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 77A3 as shown in SEQ ID NO:9 or as encoded by the clone contained in the ATCC Accession No. 209290; nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 49C9 as shown in SEQ ID NO:5 or as encoded by the clone contained in ATCC Accession No. 209291; and nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 70B11 as shown in SEQ ID NO:7 or as encoded by the clone contained in ATCC Accession No. 209292.

Please substitute the pending paragraph beginning on page 19, line 6, with the following paragraph:

Also included in the present invention are nucleic acid molecules containing a nucleotide sequence encoding an antibody heavy chain, including: nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 77A3 as shown in SEQ ID NO:15 or as encoded by the clone contained in ATCC Accession No. 209287; nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 49C9 as shown in SEQ ID NO:11 or as encoded by

the clone contained in ATCC Accession No. 209289; and nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 70B11 as shown in SEQ ID NO:13 or as encoded by the clone contained in ATCC Accession No. 209288.

In the Claims:

Please cancel claims 19-35 without prejudice or disclaimer.

Sequence Listing:

At the end of the application, please insert the sequence listing appended hereto, pages 1-57.

Remarks

No new matter has been added. The specification has been amended to add priority information, to direct the entry of the sequence listing and to provide the Accession numbers of the deposited biological material.

In accordance with 37 C.R.F. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

andrea Jo Kamag

Andrea Jo Kamage Agent for Applicant Registration No. 43,703

Date: 10 | 0 | 0 | 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

PROFESSION ELL MANON ANTONOMIA COMPANION COMPA

Version with markings to show changes made

In the Specification:

The paragraph beginning on page 1, line 9, was replaced with the following:

This application is a divisional of U.S. Appl. No. 08/934,000, filed September 19, 1997, which disclosure is hereby incorporated by reference; said U.S. Appl. No. 08/934,000 claims priority benefit to U.S. Provisional Appl. No. 60/026,356, filed September 20, 1996, which disclosure is hereby incorporated by reference

The paragraph beginning on page 18, line 19, was replaced with the following:

DNA clones containing nucleotide sequences encoding the following antibody chains were deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20862 on September 19, 1997: light chain of 77A3 (77A3 LC), ATCC Accession [No. _____] No. 209290; light chain of 49C9 (49C9 LC), ATCC Accession [No. _____] No. 209291; light chain of 70B11 (70B11 LC), ATCC Accession [No. _____] No. 209292; heavy chain of 77A3 (77A3 HC), ATCC Accession [No. _____] No. 209287; heavy chain of 49C9 (49C9 HC), ATCC Accession [No. _____] No. 209289; and heavy chain of 70B11 (70B11 HC), ATCC Accession [No. _____] No. 209288.

The paragraph beginning on page 18, line 27, was replaced with the following:

The nucleic acid molecules of the present invention include: nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 77A3 as shown in SEQ ID NO:9 or as encoded by the clone contained in the ATCC Accession [No. _____] No. 209290; nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 49C9 as shown in SEQ ID NO:5 or as encoded by the clone contained in ATCC Accession [No. _____] No. 209291; and nucleic acid molecules containing a nucleotide sequence encoding the mature light chain of 70B11 as shown in SEQ ID NO:7 or as encoded by the clone contained in ATCC Accession [No. _____] No. 209292.

The paragraph beginning on page 19, line 6, was replaced with the following:

Also included in the present invention are nucleic acid molecules containing a nucleotide sequence encoding an antibody heavy chain, including: nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 77A3 as shown in SEQ ID NO:15 or as encoded by the clone contained in ATCC Accession [No. _____] No. 209287; nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 49C9 as shown in SEQ ID NO:11 or as encoded by the clone contained in ATCC Accession [No. _____] No. 209289; and nucleic acid molecules containing a nucleotide sequence encoding the mature heavy chain of 70B11

as shown in SEQ ID NO:13 or as encoded by the clone contained in ATCC Accession $\,$

[No. ____] No. 209288.

In the Claims:

Claims 19-35 were canceled without prejudice or disclaimer.

Sequence Listing:

Sequence listing appended hereto, pages 1-57 was inserted at the end of the application.